Completed PHASE2 INTERVENTIONAL 5-arm NCT00878774

Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis

An Escalating, Multiple-dose Study in Ragweed Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Ragweed

Sponsor: Adiga Life Sciences, Inc.

Conditions Allergy

Interventions Placebo ToleroMune Ragweed

Updated 6 times since 2017 Last updated: Nov 9, 2010 Started: Apr 30, 2009 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00878774, this PHASE2 trial focuses on Allergy and remains completed. Sponsored by Adiga Life Sciences, Inc., it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Adiga Life Sciences, Inc.
Circassia Limited

Data source: Circassia Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Québec, Canada